HAMILTON, ON, Sept. 21, 2022 /PRNewswire/ - Adapsyn Bioscience Inc., a chemical bioinformatics company that discovers novel drug-like small molecules, today announced a strategic collaboration with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;NASDAQ: EVO). Under the collaboration, Evotec will have the opportunity to evaluate small molecules developed by Adapsyn as potential therapeutic candidates in proprietary and partnered drug discovery projects.
Read more at prnewswire.comAdapsyn Bioscience enters into strategic collaboration with Evotec
PR Newswire -
Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)
/Tesla%20Inc%20tesla%20by-%20Iv-olga%20via%20Shutterstock.jpg)
/Microsoft%20sign%20at%20the%20headquarters%20by%20VDB%20Photos%20via%20Shutterstock.jpg)
